Xanthine Oxidoreductase Inhibitor Use Associated With Reduced Risk of Sarcopenia and Severe Sarcopenia in Patients Undergoing Hemodialysis.

Kurajoh, Masafumi; Mori, Katsuhito; Miyabe, Mizuki; Matsufuji, Shota; Kizu, Akane; Tsujimoto, Yoshihiro; Emoto, Masanori

Kurajoh, Masafumi; Mori, Katsuhito; Miyabe, Mizuki; Matsufuji, Shota; Kizu, Akane; Tsujimoto, Yoshihiro; Emoto, Masanori.

Afiliación

Kurajoh M; Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan.
Mori K; Department of Nephrology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Miyabe M; Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan.
Matsufuji S; Division of Internal Medicine, Dialysis Center, Inoue Hospital, Osaka, Japan.
Kizu A; Division of Rehabilitation, Inoue Hospital, Osaka, Japan.
Tsujimoto Y; Division of Internal Medicine, Dialysis Center, Inoue Hospital, Osaka, Japan.
Emoto M; Division of Internal Medicine, Dialysis Center, Inoue Hospital, Osaka, Japan.

Front Med (Lausanne) ; 9: 817578, 2022.

Article en En | MEDLINE | ID: mdl-35198574

Palabras clave

AWGS 2019; XOR inhibitor; hemodialysis; prevalence; sarcopenia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Idioma: En Revista: Front Med (Lausanne) Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google